High-precision measurement of the W boson mass with the CDF II detector
…, J Guimaraes da Costa, SR Hahn, JY Han… - Science, 2022 - science.org
The mass of the W boson, a mediator of the weak force between elementary particles, is tightly
constrained by the symmetries of the standard model of particle physics. The Higgs boson …
constrained by the symmetries of the standard model of particle physics. The Higgs boson …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer,
there remains a need for effective treatments for progressive disease. We assessed the …
there remains a need for effective treatments for progressive disease. We assessed the …
[HTML][HTML] Neuronal autophagy and neurodegenerative diseases
JH Son, JH Shim, KH Kim, JY Ha, JY Han - Experimental & molecular …, 2012 - nature.com
Autophagy is a dynamic cellular pathway involved in the turnover of proteins, protein complexes,
and organelles through lysosomal degradation. The integrity of postmitotic neurons is …
and organelles through lysosomal degradation. The integrity of postmitotic neurons is …
Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion
JY Han, JY Fan, Y Horie, S Miura, DH Cui… - Pharmacology & …, 2008 - Elsevier
Ischemia and reperfusion (I/R) exerts multiple insults in microcirculation, frequently accompanied
by endothelial cell injury, enhanced adhesion of leukocytes, macromolecular efflux, …
by endothelial cell injury, enhanced adhesion of leukocytes, macromolecular efflux, …
Low-cost multi-touch sensing through frustrated total internal reflection
JY Han - Proceedings of the 18th annual ACM symposium on …, 2005 - dl.acm.org
This paper describes a simple, inexpensive, and scalable technique for enabling high-resolution
multi-touch sensing on rear-projected interactive surfaces based on frustrated total …
multi-touch sensing on rear-projected interactive surfaces based on frustrated total …
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
…, C Song, J Wang, Y Zou, GJ Anderson, JY Han… - Nature …, 2018 - nature.com
Nanoscale robots have potential as intelligent drug delivery systems that respond to
molecular triggers 1 , 2 , 3 , 4 . Using DNA origami we constructed an autonomous DNA robot …
molecular triggers 1 , 2 , 3 , 4 . Using DNA origami we constructed an autonomous DNA robot …
[HTML][HTML] Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS …
…, CA Shu, N Girard, S Viteri, JY Han… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
JY Han, K Park, SW Kim, DH Lee, HY Kim… - Journal of clinical …, 2012 - ascopubs.org
Purpose Gefitinib has shown high response rate and improved progression-free survival (PFS)
in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of gefitinib …
in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of gefitinib …
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non–small cell lung cancer
JY Han, SH Lee, NJ Yoo, LS Hyung, YJ Moon… - Clinical Cancer …, 2011 - AACR
Purpose: To evaluate the efficacy and safety of gefitinib plus simvastatin (GS) versus
gefitinib alone (G) in previously treated patients with advanced non–small cell lung cancer (NSCLC)…
gefitinib alone (G) in previously treated patients with advanced non–small cell lung cancer (NSCLC)…
[HTML][HTML] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
…, HR Kim, MJ Ahn, JCH Yang, JY Han… - … England Journal of …, 2018 - Mass Medical Soc
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
